BlossomHill Therapeutics is a small molecule drug design and development company focused on a mission to address unmet medical needs in oncology and autoimmune diseases. With a deep pipeline of candidates across a range of targets, the company aims to take the next leap forward in treatment for patients. BlossomHill Therapeutics was founded by J. Jean Cui and Y. Peter Li in 2020 and is headquartered in San Diego, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/29/2024 | Series B | $100MM | $xx.xx | $293.78MM | Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners, Plaisance Capital Management, H&D Asset Management | |
Price per Share
$xx.xx
Shares Outstanding
26,575,247
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners, Plaisance Capital Management, H&D Asset Management
|
||||||
03/01/2021 | Series A | $71MM | $xx.xx | $139.54MM | Cormorant Asset Management, Hercules BioVentures Partners, OrbiMed, Vivo Capital | |
Price per Share
$xx.xx
Shares Outstanding
26,613,546
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Cormorant Asset Management, Hercules BioVentures Partners, OrbiMed, Vivo Capital
|
||||||
12/31/2020 | Series Angel | $2MM | $xx.xx | $3.33MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
10,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|